A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
This important study is looking into a new inhaled medicine called saralutinib for a serious lung condition called pulmonary arterial hypertension (PAH). PAH makes it hard for your heart to pump blood to your lungs, causing breathlessness and tiredness. In this study, some people will get the new medicine, and others will get an identical-looking dummy inhaler (placebo). No one, not even the doctors, will know who is getting what until the study ends. The main goal is to see if the new medicine helps people walk further in six minutes after 24 weeks. The study also checks for other signs of improvement and any side effects to understand if this new treatment is safe and effective.
At a glance
What is this study about?
This study is about an investigational medicine called saralutinib, which is given as an inhaled powder. It's being tested for a serious condition called Pulmonary Arterial Hypertension (PAH). PAH is a rare disease where the blood vessels in your lungs become narrow, making it difficult for your heart to pump blood through them. This can lead to symptoms like shortness of breath, tiredness, and chest pain. Treating PAH is important because it can get worse over time.
The study is designed to carefully compare saralutinib with a 'placebo.' A placebo looks exactly like the real medicine but doesn't contain any active drug. Giving some people the new medicine and others the placebo helps doctors determine if any changes or improvements are truly due to the medicine itself, rather than other factors. This way, we can be sure about the medicine's effects. Neither you nor your doctor will know if you are receiving the active medicine or the placebo until the study is over.
The main thing researchers want to find out is whether saralutinib helps people with PAH improve their ability to walk. They will measure this by seeing how far people can walk in six minutes at the start of the study and again after 24 weeks. They'll also look at other important markers of health, like how long it takes for a person's condition to worsen, how many people show overall clinical improvement, and changes in certain blood tests. They will also carefully record any side effects to understand the medicine's safety. This type of study, called a Phase 3 study, is usually the last step before a new medicine might become available to the public.
Key takeaways
- Tests a new inhaled medicine (saralutinib) for PAH.
- Compares the new medicine to a dummy inhaler (placebo).
- Focuses on improving walking ability and overall health.
- Involves regular clinic visits and using an inhaler.
- Aims to check both how well it works and its safety.
Who may be eligible?
To be considered for this study, you must be at least 18 years old. Both men and women are welcome to take part. Since the study focuses on Pulmonary Arterial Hypertension (PAH), you would need to have a confirmed diagnosis of this condition.
There might be other specific health requirements or conditions that would mean you can't join the study. These could include certain medications you're taking, other medical problems you have, or specific results from medical tests. These detailed rules help make sure the study is safe for everyone involved and that the results are clear.
It's important to discuss your full medical history with the study doctor and team. They will go through all the criteria to determine if this study is suitable for you. They'll also ensure you understand everything before you decide to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of Pulmonary Arterial Hypertension (PAH)?
- Are you able to attend regular clinic appointments?
- Are you willing to use an inhaler as part of the study?
- Are you able to participate in a six-minute walk test?
What does participation involve?
If you decide to take part in this study, you would primarily be using an inhaler device to take your study medicine (either saralutinib or the placebo) as directed. This would be done at home. You will have regular visits to the study clinic or hospital. These visits will involve various assessments, such as physical examinations, blood tests, and heart and lung function tests. A key assessment is the 'six-minute walk test,' where you'll walk as far as you can in six minutes, as this is how the study measures how well the medicine is working.
You will receive a supply of the study medicine (inhaler capsules) at each visit. You'll also need to keep track of any symptoms or side effects you experience. The study team will provide you with information on how to do this. There will be specific follow-up appointments to monitor your health and collect data. The overall duration of your active participation in receiving the study drug and undergoing these main assessments will be 24 weeks, though there might be some follow-up calls or visits after that period.
Potential risks and benefits
Locations (16)
- —UnverifiedSpain
- —UnverifiedLithuania
- —UnverifiedGreece
- —UnverifiedFrance
- —UnverifiedDenmark
- —UnverifiedGermany
- —UnverifiedBelgium
- —UnverifiedPortugal
- —UnverifiedCzechia
- —UnverifiedLatvia
- —UnverifiedNetherlands
- —UnverifiedPoland
Common questions
What is Pulmonary Arterial Hypertension (PAH)?
PAH is a condition where the blood vessels in your lungs become narrowed, making it harder for your heart to pump blood, causing shortness of breath and tiredness.
What is a 'placebo'?
A placebo is a dummy inhaler that looks exactly like the real medicine but contains no active drug. It helps researchers see if the real medicine is effective.
What is the 'six-minute walk test'?
It's a simple test where you walk as far as you can in six minutes. It helps doctors measure how well you can exercise and how your condition is improving.
Will I know if I'm getting the new medicine or the placebo?
No, this is a 'blinded' study, so neither you nor your doctor will know until the study is over. This ensures fair and accurate results.
How long does the study last?
The main part of the study where you get the medicine and have tests will last for 24 weeks (about 6 months).
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.